Altogether, these data provide evidence that, in the context of colorectal cancer, a drop in PHD1 levels reduces p53 phosphorylation following the administration of three different chemotherapeutics commonly used in the clinical treatment of CRC. This evidence concerns the gene TP53 and colorectal carcinoma.